Partnering on the toughest challenges in multispecific antibody discovery
We collaborate with top pharmaceutical partners to unlock the full potential of complex antibody constructs across a broad range of indications.
Powered by the combination of high-throughput experimentation and machine learning (ML) our EVA™ platform uncovers unique, high-performing designs that are not accessible through traditional methods — opening up new regions of the design space for therapeutic innovation.
Our approach is grounded in partnership, combining partner expertise with EVA™’s ability to design, build and test thousands of final-format multispecific constructs in weeks. Together, we explore design space at a scale and resolution conventional methods can’t reach to deliver transformative medicines to patients who need them most.
Selected Partners
How We Partner
Flexible strategic partnerships to discover high-performing therapeutic antibodies.
Two distinct routes, structured around where you are in the discovery journey — from a therapeutic target on a whiteboard, to a known asset that needs sharper properties.
Discovery Partnership
Start from a target —
End with a novel asset.
Partners bring a therapeutic target and work alongside LabGenius to discover and develop a novel antibody from the ground up. By combining LabGenius’ ML–driven EVA™ platform with deep therapeutic and translational expertise from our partners, we jointly design and optimise entirely new assets. This integrated approach enables the rapid exploration of complex design space, unlocking differentiated candidates with the potential to address the most challenging molecular product profiles.
Target nominated
EVA™ discovery
Novel asset
Optimisation Partnership
Start from a known molecule —
End with an optimised asset.
Partners leverage the EVA™ platform to enhance and refine existing antibody assets. Starting from a known molecule, we apply combine our ML capabilities with high-throughput experimentation to systematically co-optimise key properties such as efficacy, selectivity (safety), and developability. This allows partners to maximise the value of their pipelines, unlocking improved performance and accelerating progression toward clinical development.
Known molecule
EVA™ optimisation
Optimised asset
Why Partner with Us
Why collaborate with LabGenius?
EVA™ is an AI-led, high-throughput discovery engine purpose-built for the multispecific era.
0
+
Multispecific / multivalent constructs characterised
Per Cycle
<6 weeks
Design–build–test–learn cycles
End-to-End
106+
Unique architectures explored in silico
Per Programme
High-throughput, AI-led discovery
We design, produce, test and learn from 3,000+ final format antibody constructs in a six-week cycle, uncovering high-performing multispecific and multivalent designs that conventional approaches miss.
Final-format, parts-based engineering
We assemble multispecific antibodies for direct validation in their final therapeutic configurations, so performance data reflects clinical reality, not isolated binder activity.
Navigate complex, multidimensional design spaces
Our ML models explore millions of theoretical antibody architectures simultaneously, optimising across efficacy, safety, and manufacturability in one unified workflow.
The potency–safety trade-off, solved
We generate highly selective multispecific antibodies with optimised safety windows against targets historically limited by on-target, off-tumour toxicity.
Partners
Existing partnership examples.
A track record of collaborations with leading global pharmaceutical companies — applying EVA™ across modalities, therapeutic areas, and stages of discovery.
Discovery Partnership
“This collaboration with LabGenius reflects LG Chem’s commitment to advancing innovative approaches in oncology. By combining LabGenius’ AI/ML-driven antibody discovery platform with our development expertise, we aim to accelerate the creation of differentiated, tumour-targeted therapies with the potential to address significant unmet needs in solid tumours.”
Jineon So
Vice President and Head of Business Unit, Research and Development Group
Optimisation Partnership
“LabGenius successfully delivered an exciting and innovative example of NANOBODY® optimisation using ML. This perfectly complements Sanofi’s Large Molecule Research strategy to infuse all aspects of biologics discovery and development with the latest in computation and AI.”
Maria Wendt
Global Head of Digital and Biologics Strategy
Get in Touch
